The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Decreased single‐photon emission computed tomographic {123I}β‐CIT striatal uptake correlates with symptom severity in parkinson's disease
Abstract
Previous studies have utilized single‐photon emission computed tomography (SPECT) to demonstrate decreased {123 I}β‐CIT striatal uptake in idiopathic Parkinson disease (PD) patients. The present study extendss this work by examining SPECT outcome measures in a larger group of PD patients with varying disease severity. Twenty‐eight l‐dopa‐responsive PD patients (Hoehn‐Yahr stages 1–4) and 27 healthy controls had SPECT scans at 18 to 24 hours after injection of {123 I}β‐CIT. Specific to nondisplaceable striatal uptake ratios (designated V3″) were correlated with Hoehn‐Yahr stage and Unified Parkinson's Disease Rating Scale (UPDRS) subscores. Linear discriminant function analyses utilizing striatal uptakes, putamen‐to‐caudate ratios, and ipsilateral‐contralateral asymmetry indices were performed. Decreased striatal tracer uptake (V3″) was correlated with total UPDRS score for both contralateral and ipsilateral striatum. Putamen uptake was relatively more reduced than caudate with mean putamen:caudate ratios of 0.50 ± 0.17 and 0.82 ± 0.09 for PD patients and controls, respectively. Ipsilateral:contralateral asymmetry was significantly greater in PD patients than controls. Discriminant function analysis utilizing V3″ for ipsilateral and contralateral caudate and putamen correctly classified all 55 cases. These data demonstrate Marchked differences in {123 I}β‐CIT SPECT measures in healthy controls and PD patients. The significant correlation of SPECT measures with motor severity suggests {123 I}β‐CIT may be a useful Marchker of disease severity in PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., & Seitelberger, F. (1973) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(73)90175-5 · Cited by 2,651
Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale
Fahn, S. (1987) · Medical Entomology and Zoology · Cited by 2,163
Uneven Pattern of Dopamine Loss in the Striatum of Patients with Idiopathic Parkinson's Disease
Kish, S. J., Shannak, K., & Hornykiewicz, O. (1988) · New England Journal of Medicine · doi:10.1056/nejm198804073181402 · Cited by 1,953
A Method for Attenuation Correction in Radionuclide Computed Tomography
Chang, L.-T. (1978) · IEEE Transactions on Nuclear Science · doi:10.1109/tns.1978.4329385 · Cited by 1,297
Core assessment program for intracerebral transplantations (CAPIT)
Langston, J. W., Widner, H., Goetz, C. G., Brooks, D., Fahn, S., Freeman, T., & Watts, R. (1992) · Movement Disorders · doi:10.1002/mds.870070103 · Cited by 1,008
The Prevention of Acute Gastric Ulcer in the Rat by α-Methyldopa
Djahanguiri, B., Hemmati, S., Sadeghi, D., & Firouzabadi, A. (1967) · Pharmacology · doi:10.1159/000137111 · Cited by 783
Irreversible motor impairment in young addicts ? ephedrone, manganism or both?
Sikk, K., Taba, P., Haldre, S., Bergquist, J., Nyholm, D., Zjablov, G., Asser, T., & Aquilonius, S.-M. (2007) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2007.00818.x · Cited by 665
Brooks, D. J., Ibanez, V., Sawle, G. V., Quinn, N., Lees, A. J., Mathias, C. J., Bannister, R., Marsden, C. D., & Frackowiak, R. S. J. (1990) · Annals of Neurology · doi:10.1002/ana.410280412 · Cited by 626
Innis, R. B., Seibyl, J. P., Scanley, B. E., Laruelle, M., Abi-Dargham, A., Wallace, E., Baldwin, R. M., Zea-Ponce, Y., Zoghbi, S., & Wang, S. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11965 · Cited by 359
Self-citation
Research works printed but not linked: 5
- Seibyl J, 1994, Decreased [123I]β‐CIT SPECT striatal uptake correlates with disease severity on idiopathic Parkinson's disease, Soc Neurosci Abstr, 20, 1464
- van Dyck C, 1995, AGe‐related decline in dopamine transporter binding in human striatum with [123I]β‐CIT SPECT, J Neucl Med, 36, 1175
- MarekKL SeibylJP ZoghbiSS et al. [123I]β‐CIT SPECT imaging demonstrates bilateral loss of dopamine transporters in hemiparkinson's disease. Neurology (In press)
- 10.1016/0028-3908(94)90116-3 · doi:10.1016/0028-3908(94)90116-3
- Bøttcher J, 1975, Morphology of the basal ganglia in Parkinson's disease, Acta Neurol Scand, 52, 1
Cited by
Levodopa and the Progression of Parkinson's Disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,821
The Unified Parkinson's Disease Rating Scale (UPDRS): Status and recommendations
Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease (2003) · Movement Disorders · doi:10.1002/mds.10473 · Cited by 1,810
Description of Parkinson's Disease as a Clinical Syndrome
FAHN, S. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07458.x · Cited by 977
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 908
Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD)
Defer, G.-L., Widner, H., Mari�, R.-M., R�my, P., Levivier, M., & Conference Participants: Conference Participants: G. L. Defer, M. (. (1999) · Movement Disorders · doi:10.1002/1531-8257(199907)14:4<572::aid-mds1005>3.0.co;2-c · Cited by 865
Booij, J., Tissingh, G., Boer, G. J., Speelman, J. D., Stoof, J. C., Janssen, A. G., Wolters, E. C., & van Royen, E. A. (1997) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.62.2.133 · Cited by 439
Changes in network activity with the progression of Parkinson's disease
Huang, C., Tang, C., Feigin, A., Lesser, M., Ma, Y., Pourfar, M., Dhawan, V., & Eidelberg, D. (2007) · Brain · doi:10.1093/brain/awm086 · Cited by 395
The role of radiotracer imaging in Parkinson disease
Ravina, B., Eidelberg, D., Ahlskog, J. E., Albin, R. L., Brooks, D. J., Carbon, M., Dhawan, V., Feigin, A., Fahn, S., Guttman, M., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000149403.14458.7f · Cited by 374
Self-citation[ 123 I]β-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression
Marek, K., Innis, R., van Dyck, C., Fussell, B., Early, M., Eberly, S., Oakes, D., & Seibyl, J. (2001) · Neurology · doi:10.1212/wnl.57.11.2089 · Cited by 347
Self-citationRinne, J. O., Portin, R., Ruottinen, H., Nurmi, E., Bergman, J., Haaparanta, M., & Solin, O. (2000) · Archives of Neurology · doi:10.1001/archneur.57.4.470 · Cited by 337
Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging
Frey, K. A., Koeppe, R. A., Kilbourn, M. R., Vander Borght, T. M., Albin, R. L., Gilman, S., & Kuhl, D. E. (1996) · Annals of Neurology · doi:10.1002/ana.410400609 · Cited by 314
The role of DAT-SPECT in movement disorders
Kagi, G., Bhatia, K. P., & Tolosa, E. (2010) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.157370 · Cited by 311
Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease
The Parkinson Study Group PRECEPT Investigators (2007) · Neurology · doi:10.1212/01.wnl.0000277648.63931.c0 · Cited by 292
Walker, Z. (2002) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.73.2.134 · Cited by 279
Oh, M., Kim, J. S., Kim, J. Y., Shin, K.-H., Park, S. H., Kim, H. O., Moon, D. H., Oh, S. J., Chung, S. J., & Lee, C. S. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.095224 · Cited by 276
Booij, J., Speelman, J. D., Horstink, M. W. I. M., & Wolters, E. C. (2001) · European Journal of Nuclear Medicine · doi:10.1007/s002590000460 · Cited by 264
Parkinsonian signs and substantia nigra neuron density in decendents elders without PD
Ross, G. W., Petrovitch, H., Abbott, R. D., Nelson, J., Markesbery, W., Davis, D., Hardman, J., Launer, L., Masaki, K., Tanner, C. M., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20226 · Cited by 260
Neurodegeneration and neuroprotection in Parkinson disease
Fahn, S., & Sulzer, D. (2004) · NeuroRX · doi:10.1602/neurorx.1.1.139 · Cited by 257
Positron Emission Tomography of Monoaminergic Vesicular Binding in Aging and Parkinson Disease
Bohnen, N. I., Albm, R. L., Koeppe, R. A., Wernette, K. A., Kilbourn, M. R., Minoshima, S., & Frey, K. A. (2006) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600276 · Cited by 254
Levodopa in the treatment of Parkinson's disease
Schapira, A. H. V., Emre, M., Jenner, P., & Poewe, W. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02697.x · Cited by 231
NEUROIMAGING AND NEUROPSYCHOLOGY OF THE STRIATUM
Rauch, S. L., & Savage, C. R. (1997) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70343-9 · Cited by 148
Dopamine transporter binding in Gilles de la Tourette syndrome
Müller-Vahl, K. R., Berding, G., Brücke, T., Kolbe, H., Meyer, G. J., Hundeshagen, H., Dengler, R., Knapp, W. H., & Emrich, H. M. (2000) · Journal of Neurology · doi:10.1007/pl00007806 · Cited by 95
Correlation of Parkinson's disease severity and duration with123I-FP-CIT SPECT striatal uptake
Benamer, H. T. S., Patterson, J., Wyper, D. J., Hadley, D. M., Macphee, G. J. A., & Grosset, D. G. (2000) · Movement Disorders · doi:10.1002/1531-8257(200007)15:4<692::aid-mds1014>3.0.co;2-v
Metadata
- Authors
- Seibyl, J. P., Marchek, K. L., Quinlan, D., Sheff, K., Zoghbi, S., Zea‐Ponce, Y., Baldwin, R. M., Fussell, B., Smith, E. O., Charney, D. S., Hoffer, P. B., & Innis, R. B.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 1995-10
- Volume
- 38
- Issue
- 4
- Pages
- 589-598
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W1993253047
- Cited by
- 467
- References
- 24
- FWCI
- 10.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.